Senvelgo®, a recent innovation from Boehringer Ingelheim that makes treating diabetic cats simple, safe, and highly convenient, won the 2023 Animal Health Best New Product for Companion Animals award.
S&P Global has recognised Senvelgo®, Boehringer Ingelheim’s groundbreaking feline diabetes innovation, with the Animal Health Award 2023 in the category “Best New Product for Companion Animals.” A group of independent judges chose Senvelgo® because of its indication in a new product category (SGLT2 inhibitors), its milestone approvals in the US, Canada, and Europe this year, and because it was designed specifically for cats.
“The overwhelming excitement for Senvelgo® from our customer veterinarians was a first indication of the value this product brings and the impact on the lives of cats and their owners. We are honoured to now receive this award for the Best New Product for Companion Animals,” shares Jean-Luc Michel, Head of Global Strategic Marketing Animal Health at Boehringer Ingelheim.
The Best New Product for Companion Animals award is aimed at products for dogs, cats, or horses that were commercialised in 2023 or completed their first full year of sales in 2023. The winning criteria include innovation, the product’s ability to meet unmet needs, and its success in the market.
SENVELGO® REVOLUTIONISES CARE FOR DIABETIC CATS
Senvelgo® is the first once-daily oral liquid treatment that reliably reduces blood glucose levels in cats with diabetes mellitus. It makes treating a diabetic cat simple and convenient, allowing diabetic cats and their owners to have normal lives despite the disease.
Eric Haaksma, Head of Global Innovation Animal Health at Boehringer Ingelheim, comments: “People go above and beyond to protect or treat their pets from illnesses and improve their quality of life. At Boehringer Ingelheim, our ambition is to transform the lives of animals and their owners through new approaches and innovative treatments. Senvelgo® exemplifies this ambition, and receiving this award is a wonderful recognition of the dedicated efforts of our teams.”
Senvelgo® is already being sold in veterinary clinics in the US, Great Britain, and Switzerland and has recently received regulatory approval in the European Union and Canada.
